NASDAQ: INVA
Innoviva Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their INVA stock forecasts and price targets.

Forecast return on equity

Is INVA forecast to generate an efficient return?

Company
14.51%
Industry
1,015.66%
Market
62.25%
INVA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is INVA forecast to generate an efficient return on assets?

Company
7.88%
Industry
405.65%
INVA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

INVA earnings per share forecast

What is INVA's earnings per share in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
$1.55+53.47%

INVA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
INVA$18.08N/AN/A
XNCR$16.31$32.60+99.88%Strong Buy
ETNB$10.57$36.25+242.95%Strong Buy
GYRE$11.98N/AN/A
OCUL$7.28$18.50+154.12%Buy

Innoviva Stock Forecast FAQ

What is INVA's earnings growth forecast for 2025-2025?

(NASDAQ: INVA) Innoviva's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of N/A, and while it is not forecast to beat the US market's average forecast earnings growth rate of N/A.

Innoviva's earnings in 2025 is $64,591,000.

In 2025, INVA is forecast to generate $97,031,676 in earnings, with the lowest earnings forecast at $97,031,676 and the highest earnings forecast at $97,031,676.

If you're new to stock investing, here's how to buy Innoviva stock.

What is INVA's forecast return on equity (ROE) for 2025-2025?

(NASDAQ: INVA) forecast ROE is 14.51%, which is considered weak.

What is INVA's Earnings Per Share (EPS) forecast for 2025-2025?

(NASDAQ: INVA) Innoviva's current Earnings Per Share (EPS) is $1.01. In 2025, INVA's EPS is forecast to hit $1.55 (min: $1.55, max: $1.55).

What is INVA's forecast return on assets (ROA) for 2025-2025?

(NASDAQ: INVA) forecast ROA is 7.88%, which is lower than the forecast US Biotechnology industry average of 405.65%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.